SEC Comment Letter for KALA BIO, Inc. (KALA) (CIK 0001479419) (KALA) — May 13, 2020
KALA BIO, Inc. (KALA) (CIK 0001479419)
Date: May 13, 2020 · CIK: 0001479419 · Accession: 0000000000-20-004214
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-238087
Letter
United States securities and exchange commission logo May 13, 2020 Mark Iwicki Chief Executive Officer Kala Pharmaceuticals, Inc. 490 Arsenal Way, Suite 120 Watertown, MA 02472 Re:Kala Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 7, 2020 File No. 333-238087 Dear Mr. Iwicki: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Lia Der Marderosian, Esq.
Show Raw Text
United States securities and exchange commission logo
May 13, 2020
Mark Iwicki
Chief Executive Officer
Kala Pharmaceuticals, Inc.
490 Arsenal Way, Suite 120
Watertown, MA 02472
Re:Kala Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed May 7, 2020
File No. 333-238087
Dear Mr. Iwicki:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Lia Der Marderosian, Esq.